ClinicalTrials.Veeva

Menu
Arthritis and Rheumatism Associates, LLC | Jonesboro, AR logo

Arthritis and Rheumatism Associates, LLC | Jonesboro, AR

Research site

Site insights

Top conditions

Top treatments

Upadacitinib
JNJ-77242113
ABBV-154
Adalimumab
Icotrokinra
Baricitinib
Tofacitinib
Elsubrutinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Amanda Leslie

Verified by this site

Active trials

5 of 10 total trials

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic a...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Icotrokinra

The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by ass...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Active reference comparator

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling
Systemic Lupus Erythematosus
Drug: Upadacitinib
Drug: Placebo
Recently updated

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Active, not recruiting
Rheumatoid Arthritis
Drug: Adalimumab
Drug: Upadacitinib

Trial sponsors

AbbVie logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems